Covered recipient · General Payments record
RICHARD E MILLS
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,356.41
148 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,356.41 | 148 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $244.62 | 13 |
| AbbVie Inc. | $222.80 | 18 |
| PFIZER INC. | $218.68 | 13 |
| Amgen Inc. | $177.97 | 11 |
| Novo Nordisk Inc | $164.20 | 9 |
| AstraZeneca Pharmaceuticals LP | $113.72 | 7 |
| Lilly USA, LLC | $113.41 | 7 |
| Takeda Pharmaceuticals U.S.A., Inc. | $100.83 | 7 |
| GlaxoSmithKline, LLC. | $96.15 | 5 |
| Janssen Pharmaceuticals, Inc | $95.80 | 7 |
| E.R. Squibb & Sons, L.L.C. | $88.66 | 6 |
| VIVUS LLC | $82.97 | 6 |
| Daiichi Sankyo Inc. | $72.95 | 4 |
| Biohaven Pharmaceuticals, Inc. | $72.49 | 4 |
| Eisai Inc. | $70.83 | 5 |
| Merck Sharp & Dohme Corporation | $64.15 | 4 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.31 | 3 |
| Esperion Therapeutics, Inc. | $49.64 | 3 |
| Gilead Sciences, Inc. | $45.98 | 3 |
| Amarin Pharma Inc. | $44.94 | 3 |
| Almatica Pharma LLC | $31.71 | 2 |
| Janssen Scientific Affairs, LLC | $31.66 | 2 |
| Astellas Pharma US Inc | $21.75 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.80 | 1 |
| Biogen, Inc. | $17.06 | 1 |
| Ironwood Pharmaceuticals, Inc | $15.54 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $14.79 | 1 |
| Endo Pharmaceuticals Inc. | $12.00 | 1 |
Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RICHARD E MILLS
NPI 1518919828 · CMS profile ID 250796
Allopathic & Osteopathic Physicians / Internal Medicine
MT PLEASANT, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- RICHARD E MILLS, NPI 1518919828, CMS profile ID 250796, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518919828?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
148 matching records · $2,356.41 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 148.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $14.17 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788341699 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.92 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783664613 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763535702 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.28 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820090057 | CMS |
| Daiichi Sankyo Inc. | $20.50 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836305815 | CMS |
| Amgen Inc. | $15.97 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825719983 | CMS |
| AbbVie Inc. | $9.47 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698345 | CMS |
| AbbVie Inc. | $14.18 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698339 | CMS |
| PFIZER INC. | $12.46 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832671415 | CMS |
| Biohaven Pharmaceuticals, Inc. | $17.97 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852568283 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.18 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763535704 | CMS |
| Janssen Scientific Affairs, LLC | $16.47 | 06/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788341705 | CMS |
| Gilead Sciences, Inc. | $15.45 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848241825 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.52 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829554839 | CMS |
| Esperion Therapeutics, Inc. | $19.27 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838355635 | CMS |
| Amgen Inc. | $11.59 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825719967 | CMS |
| Amgen Inc. | $21.11 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825719979 | CMS |
| Merck Sharp & Dohme Corporation | $19.39 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848365165 | CMS |
| GlaxoSmithKline, LLC. | $16.86 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803076505 | CMS |
| Novo Nordisk Inc | $19.64 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811579585 | CMS |
| VIVUS LLC | $14.96 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 814343941 | CMS |
| AbbVie Inc. | $11.73 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698335 | CMS |
| PFIZER INC. | $13.46 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832602691 | CMS |
| Daiichi Sankyo Inc. | $16.67 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836300423 | CMS |
| Lilly USA, LLC | $19.65 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818712035 | CMS |
| Amgen Inc. | $13.48 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825719955 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.93 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783664589 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.75 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763535706 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $14.79 | 05/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777698917 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.36 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850331391 | CMS |
| Lilly USA, LLC | $19.90 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818725061 | CMS |
| Gilead Sciences, Inc. | $16.17 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848241823 | CMS |
| GlaxoSmithKline, LLC. | $30.37 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802281487 | CMS |
| PFIZER INC. | $15.81 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833545383 | CMS |
| VIVUS LLC | $12.79 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 814343933 | CMS |
| Biohaven Pharmaceuticals, Inc. | $18.43 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852568281 | CMS |
| AbbVie Inc. | $12.06 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698329 | CMS |
| GlaxoSmithKline, LLC. | $14.99 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803023223 | CMS |
| Amarin Pharma Inc. | $15.21 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815059895 | CMS |
| AbbVie Inc. | $11.73 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698323 | CMS |
| AbbVie Inc. | $13.19 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698317 | CMS |
| Esperion Therapeutics, Inc. | $16.99 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838355633 | CMS |
| AbbVie Inc. | $3.53 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795698311 | CMS |
| Amgen Inc. | $22.92 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825719975 | CMS |
| Lilly USA, LLC | $19.35 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818725059 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.66 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763535708 | CMS |
| PFIZER INC. | $16.37 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832677857 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.24 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829631169 | CMS |
| Novo Nordisk Inc | $10.06 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811288929 | CMS |
| Eisai Inc. | $12.91 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817904105 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,672.41 | 7 |
| PY2025 | Principal investigator | $1,011,404.90 | 161 |
| PY2024 | Recipient | $34,409.57 | 3 |
| PY2024 | Principal investigator | $290,464.86 | 32 |
| PY2023 | Principal investigator | $714,905.39 | 52 |
| PY2022 | Principal investigator | $1,344,914.20 | 146 |
| PY2021 | Principal investigator | $1,104,673.29 | 161 |
| PY2020 | Principal investigator | $458,634.55 | 248 |
| PY2019 | Recipient | $1,360.79 | 16 |
| PY2019 | Principal investigator | $589,691.29 | 136 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
168 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $540.00 | 12/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184280700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 12/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184280702 |
| Principal investigator 1 | Genentech, Inc. | $1,895.00 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,246.75 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184278880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,097.25 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274504 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.00 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274506 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $324.00 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274510 |
| Principal investigator 1 | Genentech, Inc. | $5,672.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,534.75 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269155 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.90 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,072.25 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $32,787.45 | 11/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184265561 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 11/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,493.50 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,922.45 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,128.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,857.95 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $513.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $342.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,849.50 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $492.75 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263605 |
| Principal investigator 1 | Genentech, Inc. | $399.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,506.95 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261247 |
| Principal investigator 1 | Genentech, Inc. | $1,895.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567792 |
| Principal investigator 1 | Genentech, Inc. | $718.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567845 |
| Principal investigator 1 | Genentech, Inc. | $1,436.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567885 |
| Principal investigator 1 | Genentech, Inc. | $718.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567938 |
| Principal investigator 1 | Genentech, Inc. | $1,409.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567978 |
| Principal investigator 1 | Genentech, Inc. | $3,531.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568090 |
| Principal investigator 1 | Genentech, Inc. | $718.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568458 |
| Principal investigator 1 | Genentech, Inc. | $2,154.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568646 |
| Principal investigator 1 | Genentech, Inc. | $4,074.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211568711 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,000.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569038 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,320.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,905.07 | 11/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184257747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,160.00 | 10/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253805 |
| Principal investigator 1 | Amgen Inc. | $25,908.00 | 10/24/2025 | Non-covered Recipient Entity ACELLACARE US INC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246638801 |
| Principal investigator 1 | Amgen Inc. | $65,442.74 | 10/24/2025 | Non-covered Recipient Entity ACELLACARE US INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246638815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,151.82 | 10/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253214 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,283.17 | 10/16/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $223,921.80 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184248910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $32,873.85 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,938.00 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,072.25 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.02 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249110 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $21,431.25 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,890.00 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184249114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,118.69 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,987.05 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,425.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $540.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $741.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,296.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $924.75 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $458.85 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $108.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.50 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $768.15 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.90 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $342.00 | 10/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.38 | 09/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184242467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,118.69 | 09/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184240624 |
| Principal investigator 1 | Genentech, Inc. | $4,641.00 | 09/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566977 |
| Principal investigator 1 | Genentech, Inc. | $18,738.00 | 08/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.38 | 08/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 08/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 08/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,067.39 | 08/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226303 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 08/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226321 |
| Principal investigator 1 | Amgen Inc. | $5,686.50 | 07/28/2025 | Non-covered Recipient Entity ACCELLACARE CHARLESTON | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246638690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,740.77 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.50 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $118.80 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $477.90 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $399.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $924.75 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $325.35 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $432.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $230.85 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $399.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,191.75 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $432.00 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,626.75 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218075 |
| Principal investigator 1 | Genentech, Inc. | $1,774.00 | 07/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567332 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.38 | 07/17/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217234 |
| Principal investigator 1 | Genentech, Inc. | $6,728.00 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211567106 |
| Principal investigator 1 | Amgen Inc. | $15,988.08 | 07/08/2025 | Non-covered Recipient Entity ACCELLACARE CHARLESTON | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246638692 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $531.00 | 06/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566422 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $54.00 | 06/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566533 |
| Principal investigator 1 | H. Lundbeck A S | $1,053.02 | 06/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771520 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 06/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771548 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $887.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566356 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,548.80 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566417 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,500.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566475 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $531.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,784.43 | 06/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184205887 |
| Principal investigator 1 | Eli Lilly and Company | $9,811.00 | 06/10/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187888794 |
| Principal investigator 1 | H. Lundbeck A S | $83.57 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770730 |
| Principal investigator 1 | H. Lundbeck A S | $2,284.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770751 |
| Principal investigator 1 | H. Lundbeck A S | $295.92 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770778 |
| Principal investigator 1 | H. Lundbeck A S | $212.35 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770789 |
| Principal investigator 1 | H. Lundbeck A S | $88.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770801 |
| Principal investigator 1 | H. Lundbeck A S | $328.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770809 |
| Principal investigator 1 | H. Lundbeck A S | $137.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,784.43 | 06/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204049 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,774.00 | 05/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566343 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,436.75 | 05/21/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192138078 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,837.57 | 05/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $540.00 | 05/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $285.00 | 05/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194259 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,441.00 | 05/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211566593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,213.73 | 05/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184192745 |
| Recipient | Corcept Therapeutics | $302.47 | 05/03/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214161989 |
| Recipient | Corcept Therapeutics | $71.74 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162045 |
| Recipient | Corcept Therapeutics | $76.44 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162118 |
| Recipient | Corcept Therapeutics | $98.62 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162155 |
| Recipient | Corcept Therapeutics | $32.67 | 05/02/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162191 |
| Recipient | Corcept Therapeutics | $743.54 | 05/01/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162013 |
| Recipient | Corcept Therapeutics | $346.93 | 05/01/2025 | Covered Recipient Physician | COR311 | No dispute reported | 06/30/2026 | 1214162029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,083.51 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,598.60 | 04/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192138083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,282.38 | 04/21/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184185253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,887.13 | 04/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183466 |
| Principal investigator 1 | H. Lundbeck A S | $3,594.00 | 04/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769470 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,061.42 | 04/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184181908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,292.65 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,847.69 | 03/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174606 |
| Principal investigator 1 | H. Lundbeck A S | $4,236.00 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,847.69 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184170910 |
| Principal investigator 1 | H. Lundbeck A S | $3,651.00 | 03/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,376.59 | 03/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184156768 |
| Principal investigator 1 | Eli Lilly and Company | $164.70 | 02/25/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187887622 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,211.10 | 02/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192138090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.50 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154140 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $484.65 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154142 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $338.85 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154144 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $342.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154146 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $949.32 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $383.40 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.50 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $76.95 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $284.85 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,292.65 | 02/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184152998 |
| Principal investigator 1 | H. Lundbeck A S | $21,906.00 | 02/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766971 |
| Principal investigator 1 | Eli Lilly and Company | $500.00 | 01/31/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187889546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,083.94 | 01/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149798 |
| Principal investigator 1 | Eli Lilly and Company | $3,900.12 | 01/27/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187889540 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,602.00 | 01/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192137263 |
| Principal investigator 1 | Eli Lilly and Company | $164,154.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187887616 |
| Principal investigator 1 | Eli Lilly and Company | $26,656.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187888134 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,686.36 | 01/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184147517 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $921.00 | 01/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192138071 |